Research Abstract
My clinical work and research focuses on the evaluation of novel therapeutics for the care of women with gynecologic malignancies.
Carolyn N. Krasner, MD
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Phone: (617) 632-5369
Carolyn N. Krasner, MD
Dana-Farber Cancer Institute
EDUCATIONAL TITLES
DF/HCC PROGRAM AFFILIATION
Publications
- Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol 2020. PubMed
- Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol 2019. PubMed
- Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract 2016. PubMed
- Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer 2016. PubMed
- Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, Del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol 2016; 141:108-12. PubMed
- Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol 2015. PubMed
- Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res 2015; 21:808-18. PubMed
- Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer 2014. PubMed
- Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23:1219-25. PubMed
- del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 2013; 30:435. PubMed
- Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 2012; 48:2361-8. PubMed
- Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol 2012; 127:161-7. PubMed
- Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol 2010; 15:390-8. PubMed
- Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. J Clin Oncol 2010; 28:3107-14. PubMed
- Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol 2010; 116:168-72. PubMed
- Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2009; 28:154-9. PubMed
- Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009; 115:443-6. PubMed
- Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27:5601-6. PubMed
- Miller DS,Blessing JA,Krasner CN,Mannel RS,Hanjani P,Pearl ML,Waggoner SE,Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009; 27:2686-91. PubMed
- Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009; 123:1262-7.e1. PubMed
- Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol 2008; 112:394-9. PubMed
- Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008; 26:5761-6. PubMed
- Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med 2006; 354:1615-25. PubMed